Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2390664 | 0.76 | — | — | |
| SCHEMBL925364 | 0.73 | — | — | |
| SCHEMBL1984969 | 0.64 | — | — | |
| SCHEMBL7109983 | 0.63 | — | — | |
| SCHEMBL14688938 | 0.62 | — | — | |
| SCHEMBL892277 | 0.61 | HTT (0.41) | HTT | |
| SCHEMBL1983658 | 0.59 | TSHR (0.32) | — | |
| SCHEMBL3361342 | 0.59 | CTRC (0.33) | — | |
| SCHEMBL7732731 | 0.57 | MEN1 (0.31) | — | |
| SCHEMBL8721469 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117915912-A | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2024-04-19 | — | — | CN | disclosed |
| US-8383813-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8188139-B2 | Heterocyclic-substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120004253-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-8044064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| CN-101119968-B | Heterocyclically substituted phenyl methanone derivatives as glycine transporter 1 inhibitors | HOFFMANN LA ROCHE | 2011-08-31 | — | — | CN | disclosed |
| EP-1704148-B1 | NOVEL FUSED PYRROLOCARBAZOLES | CEPHALON INC (US) | 2011-03-02 | — | — | EP | disclosed |
| US-20100152196-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-7671064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| EP-1848694-B1 | HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 | HOFFMANN LA ROCHE (CH) | 2009-11-25 | — | — | EP | disclosed |
| US-20050143442-A1 | Novel fused pyrrolocarbazoles | CEPHALON, INC. | 2005-06-30 | — | — | US | disclosed |
| US-6872833-B2 | Adenosine receptor ligands | HOFFMANN-LA ROCHE INC. (US) | 2005-03-29 | — | — | US | disclosed |
| WO-2004089949-A1 | 7-([1,4]DIOXAN-2-YL)-BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204584-A1 | ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-14 | — | — | US | disclosed |
| EP-1107756-A4 | NOVEL ISOXAZOLINONE ANTIBACTERIAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2003-02-26 | — | — | EP | disclosed |
| US-20020094984-A1 | Novel isoxazolinone antibacterial agents | SNYDER LAWRENCE B (US) | 2002-07-18 | — | — | US | disclosed |
| US-6420349-B1 | POTENT ANTIBIOTIC ACTIVE AGAINST GRAM-POSITIVE BACTERIA; ANIMAL FEED;FOOD PRESERVATIVES; WATERBASED PAINTS; WHITE WATER OF PAPER MILLS; DISINFECTANTS FOR MEDICAL AND DENTAL EQUIPMENT | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-16 | — | — | US | disclosed |
| CN-1314813-A | Novel isoxazolinone antibacterial agent | BRISTOL MYERS SQUIBB CO (US) | 2001-09-26 | — | — | CN | disclosed |
| EP-1107756-A1 | NOVEL ISOXAZOLINONE ANTIBACTERIAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000010566-A1 | NOVEL ISOXAZOLINONE ANTIBACTERIAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143442-A1 | Novel fused pyrrolocarbazoles | PC, PYCR1, CYP11B2 | NPC1 132/4885RAB9A 2196/4885HTT 210/4885 |
| US-20100152196-A1 | Novel Fused Pyrrolocarbazoles | PC, PYCR1, CYP11B2 | NPC1 132/4885RAB9A 2196/4885HTT 210/4885 |
| US-20040204584-A1 | ADENOSINE RECEPTOR LIGANDS | ADORA1, ADORA2A, ADORA3 | NPC1 1169/4885RAB9A 1366/4885HTT 4522/4885 |
| US-20020094984-A1 | Novel isoxazolinone antibacterial agents | RPS4X, RPS4Y1, CYP51A1 | NPC1 1475/4885RAB9A 1575/4885HTT 4807/4885 |
| US-20120004253-A1 | Novel Fused Pyrrolocarbazoles | PC, PYCR1, CYP11B2 | NPC1 132/4885RAB9A 2196/4885HTT 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.